Objective To evaluate the clinical therapeutic effect and safety of western medicine plus Shenfu Injection versus simple western medicine in heart failure (HF) patients. Methods Such databases as CNKI (January 1979 to 2009), VIP (January 1989 to December 2009), CBM (1978 to 2009), PubMed (1978 to December 2009), The Cochrane Library (Issue 4, 2009) and relevant journals were searched, and the literature of randomized controlled trials comparing the combination of western medicine and Shenfu Injection with simple western medicine in HF patients was included. The quality of studies was evaluated according to the methods of the Cochrane Collaboration, the data were extracted; and meta-analyses were performed with RevMan5.0.2 software. Results Sixteen trials involving 1 117 patients were included. The results of meta-analyses showed that compared with the simple western medicine treatment, the combination of western medicine and Shenfu Injection therapy significantly improved the symptoms, clinical comprehensive effect (RR=3.30, 95%CI 2.22 to 4.92, Plt;0.000 01), TCM syndrome and patient’s quality of life (RR=6.85, 95%CI 2.90 to 16.17, Plt;0.000 01), increased left ventricular ejection fraction (WMD=3.54, 95%CI 2.78 to 4.30, Plt;0.000 01), and reduced LVSD (WMD=2.43, 95%CI 1.04 to 3.82, P=0.000 6). Meanwhile, only one trail indicated that the combination of western medicine and Shenfu Injection might increase the six-minute walking distance, reduce the level of IL-6 and TNF-α, and eliminate the Lee’s HF and LVD-36 questionnaire integral. Conclusion The therapeutic effect of combining western medicine with Shenfu Injection therapy on HF patients is better than that of simple western medicine treatment.
Objective To investigate the status of clinical practices and side effects related to Shenfu injection.Method We searched the China National Knowledge Infrastructure (CNKI) database using the key word “Shenfuinjection”. Original clinical studies of Shenfu injection which were published from January 1993 to December 2008 inChinese magazines were included. Results A total of 576 relevant clinical studies were identified. There were 21 496 cases in the study group and excluding the control group patients. We investigated and analyzed the side effects of Shenfu injection. For cases with side effects, the medication dosage, the diseases for treatment, the method of medication, the menstruum, and course of treatment for the side effects were evaluated. All the side effects were mild except one case of anaphylactic shock. Conclusion Shenfu injection has been widely used in clinical patients since it came into the market in 1993. However, systematic evaluation of its clinical application is lacking, and there are some unsolved problems and deficiency in selecting and expanding diseases for treatment, evaluating the dosage and treatment method, and investigating the side effects of the drug. Therefore, it is imperative to enhance the evaluation drugs and good clinical application after the drugs come into the market with evidence-based medicine.
ObjectiveTo evaluate the clinical efficacy of shenfu injection in reducing the side effects of chemotherapy in patients with cancer. MethodsWe searched Medline, PubMed, EMbase, VIP, Chinese science and technology periodical database full text database, China journal full database, Chinese biomedical literature database, and WANFANG database the durationi was from January 1994 to May 2013 for controlled trials about the use of shenfu injection to reduce the side effects of chemotherapy, without any language limitations. The quality of literature was evaluated by Jadad rating scale, and the included trials were analyze for systematic review. ResultsA total of 30 articles were included, and all of them were from Chinese literature. There were altogether 2039 cases. Compared with single chemotherapy group, the normal rate of white blood cells [RR=1.54, 95%CI (1.28, 1.84), P<0.0000 1], hemoglobin [RR=1.30, 95%CI (1.14, 1.48), P<0.000 1], platelet [RR=1.39, 95%CI (1.19, 1.62), P<0.000 1], and the number of patients without vomiting or sickness [RR=1.54, 95%CI (1.30, 1.81), P<0.0000 1] in the shenfu treatment group were all significantly higher. The life quality of the shenfu treatment group was also obviously better than the single chemotherapy group. ConclusionCompared with single chemotherapy, shenfu injection can reduce the peripheral blood cell reduction, gastrointestinal reaction and improve the patients' quality of life. Because the quality of included studies in this research is generally low, it is necessary to design a more reasonable and strict experiment with a large sample to get an exact conclusion.
ObjectiveTo investigate the protective effect of Shenfu injection on liver injury in rats with hind limb ischemia-reperfusion and its mechanism. MethodsSixty-four male rats were randomly divided into sham operation group, ischemia-reperfusion group, Shenfu group〔Shenfu injection 7.5 mL/kg injection of peritoneal(ip), given 10 min before ischemia-reperfusion〕, Shenfu+Znpp group(Shenfu injection 7.5 mL/kg+Znpp 5 mg/kg ip, given 10 min before ischemia-reperfusion), 16 rats in each group. The rat model of hind limb ischemia-reperfusion injury was reproduced by occluding the hind limb artery of the rats for 3 h and subsequent reperfusing for 4 h. The liver tissues were gathered for malondialdehyde(MDA)and superoxide dismutase(SOD)determination. The expression of hemeoxygenase 1(HO-1)protein in the liver tissues was detected by immunohistochemistry. The pathological changes of liver were observed under the light microscope. The changes of serum glutamate-pyruvate transaminase(GPT)and glutamine oxaloacetic transaminase(GOT)were observed respectively. Results①Compared with the sham operation group, the contents of MDA, GPT, GOT, and the expression of HO-1 protein were markedly increased in the ischemia-reperfusion group, Shenfu group, and Shenfu+Znpp group(P < 0.05), the activities of SOD were markedly decreased in the ischemia-reperfusion group and Shenfu+Znpp group(P < 0.05).②Compared with the ischemia-reperfusion group, the contents of MDA, serum GPT, GOT, and the expression of HO-1 protein were markedly decreased, the activity of SOD was markedly increased in the Shenfu group(P < 0.05).③Compared with the Shenfu group, the contents of MDA, GPT, GOT were markedly increased, the activity of SOD was markedly decreased in the Shenfu+Znpp group(P < 0.05). Unde ther light microscope, the pathological changes induced by ischemia-reperfusion were significantly attenuated by the Shenfu injection in the Shenfu group and were reversed by the Znpp in the Shenfu+Znpp group. ConclusionShenfu injection inhibits liver tissue injury during hind limb ischemia-reperfusion, this protective effect might be partly through induction of HO-1.